Ironwood Pharmaceuticals to Present New Data on Once-Weekly

01.05.2024 - Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a ... Seite 1

Related Keywords

Michael Shetzline , Drug Administration , Center Trial , Ironwood Pharmaceuticals , Apraglutide Once Weekly , Short Bowel Syndrome , Intestinal Failure , Global Phase , Placebo Controlled Trial , Bowel Morphology , Motility Assessed , Short Bowel Syndrome Intestinal Failure , Colon In Continuity Treated , Support Weaning , Clinical Benefit , Improved Patient Reported Outcomes , Long Acting Glucagon Like , Analog Apraglutide , Increased Oral Intake , Improved Energy , Carbohydrate Absorption , Gastric Emptying , Healthy Individuals , Single Center Trial , Bowel Syndrome , Ironwood Pharmaceuticals Registereda Chart , Ronwood Pharmaceuticals Registereda Kurs , Ronwood Pharmaceuticals Registereda Aktie ,